Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Geron Corp.

www.geron.com

Latest From Geron Corp.

Pipeline Watch: Phase III Readouts For Talazoparib, Ampion, Avatrombopag

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase II Readouts With SPK-8011, Velusetrag, GBR-830

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Imetelstat Trial Update Lift Geron, Despite Indecision By Partner J&J

News of continuation of myelofibrosis and myelodysplastic syndromes studies well-received in market, despite global partner J&J's apparent reluctance to commit to imetelstat for the long haul.

Clinical Trials Blood & Coagulation Disorders

Misery In Myelofibrosis: Pacritinib Setback A Boost For Jakafi

With the commercial opportunity in the myelofibrosis market expected to double to over $1bn in the next five years, competition to Incyte/Novartis's Jakafi seems further away than ever as CTI BioPharma pulls the European regulatory filing for pacritinib.

Research & Development Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Geron Corp.
  • Senior Management
  • John A Scarlett, MD, Pres. & CEO
    Olivia K Bloom, EVP, Fin. & CFO
    Melissa A Behrs, EVP, Bus. Dev.
    Andrew J Grethlein, PhD, EVP, Dev. & Technical Operations
  • Contact Info
  • Geron Corp.
    Phone: (650) 473-7700
    149 Commonwealth Dr.
    Menlo Park, CA 94025
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register